Evidence map›Paper›PMID 36493961›Full record

ArticleToxicology letters2023

Tris(1,3-dichloro-2-propyl) phosphate is a metabolism-disrupting chemical in male mice.

Sara Y Ngo Tenlep, Megan Weaver, Jianzhong Chen, Olga Vsevolozhskaya, Andrew J Morris, Cetewayo S Rashid

Open access · hybridAbstract read
In one paragraph

Article in Toxicology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sara Y Ngo TenlepDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.
Megan WeaverDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA.
Jianzhong ChenDivision of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.
Olga VsevolozhskayaDepartment of Biostatistics, University of Kentucky, Lexington, KY, USA.
Andrew J MorrisDivision of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington, KY, USA; Lexington Veterans Affairs Healthcare System, Lexington, KY, USA.
Cetewayo S RashidDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA; Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY, USA. Electronic address: cetewayo.rashid@uky.edu.
University of Kentucky · USLexington VA Health Care System · US

Funding

Pilot Project ProgramP30ES026529 · NIEHS · UNIVERSITY OF KENTUCKY · PI Jason Unrine · 2017 to 2026
$15.4M
Pilot Projects ProgramP30GM127211 · NIGMS · UNIVERSITY OF KENTUCKY · PI CASSIS, LISA A · 2018 to 2022
$5.7M
Lysophosphatidic Acid and Cardiovascular Disease RiskI01BX005637 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J, SMYTH, SUSAN S. · 2021 to 2024
–
BLRD VA I01 BX005637NIEHS NIH HHS P30 ES026529NIGMS NIH HHS P30 GM127211
6 · The paper itself

Abstract

Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) is an organophosphate flame retardant. The primary TDCPP metabolite, bis(1,3-dichloro-2-propyl) phosphate (BDCPP), is detectable in the urine of over 90 % of Americans. Epidemiological studies show sex-specific associations between urinary BDCPP levels and metabolic syndrome, which is an established risk factor for type 2 diabetes, heart disease, and stroke. We used a mouse model to determine whether TDCPP exposure disrupts glucose homeostasis. Six-week old male and female C57BL/6J mice were given ad libitum access to diets containing vehicle (0.1 % DMSO) and TDCPP resulting in the following treatment groups: 0 mg/kg/day, 0.02 mg/kg/day, 1 mg/kg/day, or 100 mg/kg/day. After being on the experimental diet for five weeks without interruption, body composition was analyzed, glucose and insulin tolerance tests were performed, and fasting glucose and insulin levels were quantified. TDCPP at 100 mg/kg/day caused male sex-specific adiposity, fasting hyperglycemia, and insulin resistance. TDCPP-induced modulation of nuclear receptor activation was investigated using an in vitro screen to identify potential mechanisms of metabolic disruption. TDCPP activated farnesoid X receptor (FXR) and pregnane X receptor (PXR), and inhibited the androgen receptor (AR). PXR target genes, but not FXR target genes, were upregulated in livers from mice exposed to 100 mg TDCPP/kg/day. Interestingly, PXR target genes were differentially expressed in livers from both males and females. It remains to be determined whether TDCPP-induced metabolic disruption occurs via modulation of nuclear receptor activity. Taken together, these studies build upon the association of TDCPP exposure and metabolic syndrome in humans by identifying sex-specific effects of TDCPP on glucose homeostasis in mice.

Indexed as

Flame RetardantsMetabolic SyndromeOrganophosphorus CompoundsAnimalsDiabetes Mellitus, Type 2FemaleHumansInsulin ResistanceMaleMiceMice, Inbred C57BLReceptors, Cytoplasmic and Nuclearbis(1,3-dichloropropyl)phosphateFlame RetardantsOrganophosphorus CompoundsReceptors, Cytoplasmic and Nucleartris(1,3-dichloro-2-propyl)phosphateBody compositionGlucose toleranceInsulin resistanceNuclear receptorOrganophosphate flame retardantTDCPP

Identifiers

PMID36493961
PMCPMC9869283
OpenAlexW4311743323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.